Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Lung Neoplasms 4Non Small Cell Lung Cancer Metastatic 3Neoplasms 2Recurrence 1Neoplasm Metastasis 1Neoadjuvant Non-Small Cell Lung Cancer 1Lymphoma, Large-Cell, Anaplastic 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Docetaxel 5S 1 (combination) 2Carboplatin 2zimberelimab 1surufatinib 1quemliclustat 1pemigatinib 1nimotuzumab 1lorlatinib 1cemiplimab 1Vinorelbine 1Pemetrexed 1Paclitaxel 1Gene Expression Profiling 1Gemcitabine 1Erlotinib Hydrochloride 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Non-Small Cell Lung Cancer × lorlatinib × Clear all
NCT07415005 2026-05-05

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Thoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡